+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gynecological Cancer Drugs Market by End User (Clinics, Hospitals, Specialty Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Administration Route, Drug Class, Cancer Type - Global Forecast 2025-2030- Product Image
Gynecological Cancer Drugs Market by End User (Clinics, Hospitals, Specialty Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Administration Route, Drug Class, Cancer Type - Global Forecast 2025-2030- Product Image
Sale

Gynecological Cancer Drugs Market by End User (Clinics, Hospitals, Specialty Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Administration Route, Drug Class, Cancer Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887490
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gynecological cancer drugs market is undergoing rapid transformation as personalized treatment, regulatory evolution, and partnership strategies steer the future of patient care. Senior decision-makers face an increasingly complex environment demanding data-driven strategies to ensure both innovation and patient access across global markets.

Market Snapshot: Gynecological Cancer Drugs Market Growth

In 2024, the gynecological cancer drugs market reached USD 10.35 billion and is projected to grow to USD 11.63 billion in 2025. With a compound annual growth rate (CAGR) of 12.22%, market valuation is forecasted to hit USD 20.68 billion by 2030. These dynamics reflect the sector’s resilience and the urgent need for advanced therapeutics addressing diverse patient populations and unmet clinical needs.

Scope & Segmentation

  • End Users: Clinics (including oncology and outpatient clinics), hospitals (private and public), and specialty centers.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies.
  • Administration Routes: Intraperitoneal, intravenous (bolus and infusion), and oral (capsule and tablet) regimens.
  • Drug Classes: Chemotherapy agents (alkylating agents, platinum compounds, taxanes), hormonal therapies (anti-estrogens, aromatase inhibitors), immunotherapies (checkpoint inhibitors, vaccines), and targeted therapies (angiogenesis inhibitors, PARP inhibitors, tyrosine kinase inhibitors).
  • Cancer Types: Cervical, endometrial, ovarian, and vulvar cancers.
  • Regional Analysis: Americas (incorporating United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Company Coverage: F. Hoffmann-La Roche Ltd, AstraZeneca PLC, Merck & Co., Inc., GlaxoSmithKline plc, Clovis Oncology, Inc., Pfizer Inc., Novartis AG, Johnson & Johnson, Eisai Co., Ltd, Amgen Inc.

Key Takeaways for Senior Decision-Makers

  • Emerging therapies are moving beyond broad-spectrum treatments toward patient-specific regimens, emphasizing efficacy and safety.
  • Adoption of genomic profiling and digital health tools is accelerating personalized medicine and adaptive treatment pathways.
  • Strategic alliances between pharmaceutical and biotechnology organizations are hastening clinical innovation and drug pipeline expansion.
  • Expanding care delivery models and distribution channels are critical for improving access and meeting complex procurement requirements.
  • Understanding regional payer ecosystems and infrastructure nuances is essential for designing successful market entry and access strategies.

Tariff Impact: Navigating U.S. Regulatory Shifts in Oncology Supply Chains

The 2025 United States tariff adjustments introduce additional complexity to the global oncology drug supply chain. These regulatory changes are prompting pharmaceutical companies to realign sourcing strategies for critical active ingredients, diversify supplier bases, and invest in local production hubs. Healthcare providers and payers are responding through procurement innovation, such as strategic stockpiling and renegotiation of reimbursement frameworks, to safeguard continuity of care and manage pricing volatility throughout the value chain.

Methodology & Data Sources

This research integrates semi-structured interviews with oncologists, pharmacoeconomists, and regulatory experts. Secondary validation draws from peer-reviewed literature, health authority publications, clinical trial databases, and proprietary patent sources, all undergoing multi-tiered verification and triangulation by subject matter specialists.

Why This Report Matters

  • Enables senior leaders to anticipate market shifts and proactively refine their investment, procurement, and access strategies in the gynecological cancer drugs market.
  • Delivers actionable intelligence on the impacts of evolving technologies, tariff changes, and regulatory policies on stakeholder operations and patient access.
  • Points the way to high-potential partnerships and segment-specific opportunities that can be aligned with organizational strengths and regional dynamics.

Conclusion

This report provides clarity on the evolving oncology therapeutics environment, allowing decision-makers to shape robust, future-directed strategies. The findings support informed action in a market shaped by innovation, collaboration, and regulatory transformation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Clinical integration of PARP inhibitors with immunotherapy in front-line ovarian cancer management
5.2. Expansion of antibody-drug conjugates targeting folate receptor alpha in advanced cervical cancer
5.3. Emergence of oral selective estrogen receptor downregulators for personalized endometrial carcinoma therapy
5.4. Real-world evidence supporting maintenance bevacizumab retreatment strategies in recurrent ovarian cancer patients
5.5. Advances in predictive biomarker development for early detection of vulvar and vaginal malignancies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gynecological Cancer Drugs Market, by End User
8.1. Introduction
8.2. Clinics
8.2.1. Oncology Clinics
8.2.2. Outpatient Clinics
8.3. Hospitals
8.3.1. Private Hospitals
8.3.2. Public Hospitals
8.4. Specialty Centers
9. Gynecological Cancer Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Gynecological Cancer Drugs Market, by Administration Route
10.1. Introduction
10.2. Intraperitoneal
10.3. Intravenous
10.3.1. Bolus
10.3.2. Infusion
10.4. Oral
10.4.1. Capsule
10.4.2. Tablet
11. Gynecological Cancer Drugs Market, by Drug Class
11.1. Introduction
11.2. Chemotherapy Agents
11.2.1. Alkylating Agents
11.2.2. Platinum Compounds
11.2.3. Taxanes
11.3. Hormonal Therapy
11.3.1. Anti-Estrogens
11.3.2. Aromatase Inhibitors
11.4. Immunotherapy
11.4.1. Checkpoint Inhibitors
11.4.2. Vaccines
11.5. Targeted Therapy
11.5.1. Angiogenesis Inhibitors
11.5.2. PARP Inhibitors
11.5.3. Tyrosine Kinase Inhibitors
12. Gynecological Cancer Drugs Market, by Cancer Type
12.1. Introduction
12.2. Cervical Cancer
12.3. Endometrial Cancer
12.4. Ovarian Cancer
12.5. Vulvar Cancer
13. Americas Gynecological Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gynecological Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gynecological Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. AstraZeneca PLC
16.3.3. Merck & Co., Inc.
16.3.4. GlaxoSmithKline plc
16.3.5. Clovis Oncology, Inc.
16.3.6. Pfizer Inc.
16.3.7. Novartis AG
16.3.8. Johnson & Johnson
16.3.9. Eisai Co., Ltd
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GYNECOLOGICAL CANCER DRUGS MARKET: RESEARCHAI
FIGURE 26. GYNECOLOGICAL CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. GYNECOLOGICAL CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. GYNECOLOGICAL CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 161. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 164. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 165. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 170. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 171. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 172. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 173. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 174. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 175. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 178. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 179. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 180. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 181. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 184. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 185. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 186. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 187. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 196. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 197. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 200. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 201. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 205. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 206. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 207. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 208. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 209. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 210. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 211. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 212. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-20

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Gynecological Cancer Drugs market report include:
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eisai Co., Ltd
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.68 Billion
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gynecological Cancer Drugs - Global Strategic Business Report - Product Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Gynecological Cancer Drugs Market Report 2025 - Product Image

Gynecological Cancer Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Next-Generation Gynecological Cancer Diagnostics Market by Technology, Application, Product, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market by Technology, Application, Product, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Next-Generation Gynecological Cancer Diagnostics Market Report 2025 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Women's Health Therapeutics Market by Therapeutic Area (Cancer Therapies, Contraceptives, Gynecological Disorders), Product Type (Biologics, Devices, Drugs), Distribution Channel, End-User - Global Forecast 2025-2030 - Product Image

Women's Health Therapeutics Market by Therapeutic Area (Cancer Therapies, Contraceptives, Gynecological Disorders), Product Type (Biologics, Devices, Drugs), Distribution Channel, End-User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From

About the Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs market is a specialized segment within the broader domain of Oncology Drugs, focusing on medications used in the prevention and treatment of cancers affecting the female reproductive organs. This category encompasses drugs for ovarian, cervical, uterine/endometrial, and other less common gynecologic cancers. Advances in the understanding of the pathophysiology of gynecologic cancers have led to the development of targeted therapies, immunotherapy, hormone therapies, and chemotherapy agents. The growth in this market is driven by a rising prevalence of gynecological cancers, increased awareness of women's health, and ongoing research and development leading to more precise and personalized treatment options. In the landscape of the Oncology Drugs sector, gynecological cancer treatments are vital because they address a distinct and critical patient population. Various market participants often collaborate with research institutions and engage in clinical trials to enhance existing treatments and innovate new therapeutic solutions, facilitating progress in women's oncological care. Prominent companies operating in the Gynecological Cancer Drugs market include Roche Holding AG, AstraZeneca, Novartis AG, Pfizer Inc., and Bristol-Myers Squibb Company. These firms are pivotal in the research and production of drugs that cater to gynecological oncology, continually advancing the standards of care through therapeutic breakthroughs and extensive research initiatives. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.